CTN Bulletin logo
April 21, 2017   

CTN-0071 EHR-DARE Call to Action!



Time is running out to complete your CTN-0071 (Electronic Health Records Data Elements Research; EHR-DARE) online surveys!

If you have been identified to participate but have not yet completed your survey, you still have time -- but the clock is ticking!

The survey deadline has been slightly extended to allow busy participants to still take part. If you have been contacted to complete the survey, you will receive a couple more reminders over the next few weeks.

Please keep an eye out for emails from EHR-DARE@duke.edu -- you may reply to those messages with any questions or comments. The participation will help improve future substance use disorder research and CTN collaborations!

The CTN-0071 EHR-DARE project consists of three components:

  1. AIM 1 Investigator and Clinicians online survey
  2. AIM 2 Wave 1 Health IT online survey
  3. AIM 2 Wave 2 Clinical Workflow telephone interview

You may be invited to participate in one or more portions of the study!

Questions about the study can be sent to Micki Roseman or call 919-257-3298 or 704-250-5857.

Thank you for helping with EHR-DARE!

· · · · · · · · · · · · · · · · · · · · · · ·

From the Addiction Technology Transfer Center (ATTC)

New ATTC Resource:
Searchable Pre-Service Educational Resources: Educational materials that can support the education of a variety of professionals (doctors, nurses, social workers, etc.) regarding substance use disorders.

ATTC Messenger, April 2017: Featured article by Svetlana Yarosh and Sabirat Rubya: "Technology in Recovery: Online Videochat Meetings."

ATTC/NIATx Service Improvement Blog: Recent posts about alcohol culture in Wisconsin, introducing the BASIS (Brief Addiction Science Information Source), testing your knowledge of problem gambling, and more!

CTN Trial Progress

GraphStudy results for Open Studies as of the April 19 trial Progress Report.

CTN-0050 - Long Term Follow-up to CTN-0027: Enrolled 877 (original N=1,267 START Study participants)

CTN-0051 - X-BOT (Extended Release Naltrexone vs. Buprenorphine for Opioid Treatment). Enrolled 570

CTN-0051-A2 - Detoxification TAU. Enrolled 211

CTN-0056-Ot - Testing and Linkage to HIV Care in China. Enrolled 478

CTN-0064 - Linkage to HCV Care. Enrolled 113

Total Enrolled in all Studies: 24,219

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

journal coversNew from the CTN Dissemination Library

The Prescription Opioid Addiction Treatment Study: What Have We Learned. Weiss RD and Rao V. Drug and Alcohol Dependence 2017;173:48-S54. Get article. . .

Predictors and Outcomes of Twelve-Step Sponsorship of Stimulant Disorders: Secondary Analyses of a Multisite Randomized Clinical Trial. Wendt D, et al. Journal of Studies on Alcohol and Drugs 2017;78:287-295. Get article. . .

Sociodemographic and Substance Use Disorder Determinants of HIV Sexual Risk Behavior in Men and Women in Outpatient Drug Treatment in the NIDA National Drug Abuse Treatment Clinical Trials Network. Kidd JD, et al. Substance Use & Misuse 2017 (in press). Get article. . .

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

News from the Nodes

Northeast Node: CPDD Advocacy Day

Alan Budney, PhD, Northeast Node of the CTN Core Investigator and President-Elect of the College on Problems of Drug Dependence (CPDD) lobbied for science on addiction as part of a CPDD Advocacy Day.

Dr. Budney visited the offices of New Hampshire's two Senators, Maggie Hassan and Jeanne Shaheen, as well as the offices of Senator Chuck Grassley of Iowa and Senator Diane Feinstein of California, who are both part of the Senate Caucus on International Narcotics Control.

Highlights from CPDD Advocacy Day
Several CPDD members, including about half of the Board of Directors, attended an Advocacy Day event on March 28, 2017 and met with 28 Congressional offices. Agenda items included requests for FY2017 support for funding of $34.1 billion for NIH and $1.1 billion for NIDA, and a FY2018 $2 billion increase over the FY2017 level for NIH and a proportionate increase for NIDA.

They also requested inclusion of a "drug abuse" category on the list of research areas eligible to compete for funding within the Peer-reviewed Medical Research Program in the FY2018 Department of Defense Appropriations bill, and inclusion of a special appropriation or alternative funding mechanism for NIH's Adolescent Brain and Cognitive Development (ABCD) study.

Members requested an exemption for academic research on synthetic compounds listed in various synthetic drugs bills and provided general education to the congressional offices about drug abuse, including the consequences of using drugs and efforts to combat this problem.

Thanks to those who contributed their time, money, and energy to this important event! Read more about CPDD Advocacy Day here: http://cpdd.org/wp-content/uploads/2017/03/2017-Highlights-from-CPDD-Advocacy-Day.pdf

Follow the Northeast Node on Twitter and Facebook for updates!


Mid-Atlantic Node: DAD Special Issue

Recently hitting the newsstands is a 9-article supplement of the prestigious journal, Drug and Alcohol Dependence, entitled Prescription Opioids: New Perspectives and Research on their Role in Chronic Pain Management and Addiction.

Guest editors Maxine Stitzer, Robert Schwartz, and George Bigelow of the Mid Atlantic Node are grateful to the CTN for supporting the supplement and grateful for the skill and enthusiasm of the invited authors that include individuals both with and without CTN affiliation.

The supplement papers tell a story of the prescription opioid epidemic: the role of opioids in pain management, the advent of adverse consequences as opioid prescribing increased and the initiatives that are being implemented to staunch the flow of prescription opioids and address public health consequences.

First authors of the supplement papers include well known experts in the field of opioid epidemiology (Ted Cicero), pain management (David Tompkins; Walter Ling), overdose education (Kelly Dunn), prescription drug monitoring programs (Peter Kreiner), physician guidelines and training (Kelly Barth; Kathleen Brady), treatment interventions (Roger Weiss), physician supply for SUD treatment (Hannah Knudsen), and behavioral interventions for chronic pain treatment (Eric Garland).

This journal supplement adds to the growing literature on these inter-related topics and expands on some key areas with papers that provide insights and new data.

The issue is now available online to journal subscribers: check it out here!

Western States Node: Congrats to CODA!

CODA, a charter CTN community treatment program and frequent participant in CTN protocols, honored OHSU physician Honora Englander with the 2017 Advocacy Award for her role in the development and leadership of OHSU’s Improving Addiction Care Team (IMPACT).

IMPACT addresses the multi-faceted needs of hospitalized patients with alcohol and drug use disorders that complicate medical care for co-morbid conditions. IMPACT initiates addiction treatment services while patients are hospitalized and links them with community-based services for substance use disorders, housing, employment, and criminal justice. Many IMPACT patients continue medical and substance abuse services at CODA.

Dr. Englander received the award April 4, 2017 at CODA’s annual Advocacy Awards Luncheon.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Trainings, Webinars, Conferences

Addiction Health Services Research Conference, October 18-30, 2017

Abstracts and Investigator Award applications due by Friday, April 28! Registration for AHSR 2017 will also open soon. Rates will be:

  • $475 Early Bird (until July 31)
  • $600 Regular (after July 31)
  • $375 Student (undergrads, grads, med students only; not residents, fellows, or post-docs)

Visit the AHSR 2017 web site for details on how to submit your abstract and apply for travel awards. You'll also find information about mentor/mentoree opportunities, hotel and travel details, and more. Questions? Contact dfmchAHSR2017@fammed.wisc.edu. See you in October!

Upcoming CTN Webinars

NIDA Phenotyping Battery, April 21, 1-2pm EDT

This webinar, presented by Tanya Ramey, MD, PhD, Medical officer at NIDA, is about deep phenotyping in addictions. It will present the NIDA Phenotyping Battery, comprised of psychometric scales and behavioral tasks (with resting state imaging where possible) aligned by addictions-relevant domains with an emphasis on the ability to be implemented in extramural studies. Why use deep phenotyping for substance use disorder? To make progress in treatment for addictions, we need to step beyond the DSM 4 and 5 with their outcome-based symptoms definitions.

Read more and find instructions to connect here . . .

Potential Benefits of Increased Use of Prescription Monitoring Programs, April 27, 1-2pm EDT

This webinar, presented by Dr. Thomas Alfieri of Purdue Pharma, will outline the potential benefits of Prescription Monitoring Program use and explore ways that these benefits can be measured, using as a model Virginia's newly formed public-private partnership to enhance utilization of the state's PMP program. The Commonwealth of Virginia will connect the state PMP to the electronic medical records used by VA prescribers and pharmacists, with a goal to improve the performance, access, and usability of the PMP program data for 18,000 prescribes and 400 pharmacies in the state by the end of the year.

Read more and find instructions to connect here. . .

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·


Published by the CTN Dissemination Library of the Pacific Northwest Node
Alcohol & Drug Abuse Institute, University of Washington

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol & Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

Unsubscribe | Subscribe

Copyright (C) 2016 Alcohol and Drug Abuse Institute. All rights reserved.